Loading organizations...
Bausch + Lomb is a global eye health company developing, manufacturing, and marketing a comprehensive portfolio of vision products. These offerings span contact lenses, lens care, over-the-counter remedies, prescription pharmaceuticals, and surgical devices, addressing various eye conditions and visual correction needs.
The company began in 1853 in Rochester, New York, when optician John Jacob Bausch opened an optical goods shop. Facing early challenges, Bausch formed a partnership with friend Henry Lomb, a cabinet maker, who provided a critical $60 loan. This agreement allowed the business to expand, evolving from repairs into manufacturing its own diverse optical products.
Bausch + Lomb serves eye care professionals and patients globally with solutions across the continuum of eye health. The company’s vision focuses on improving lives by enhancing sight, achieved through sustained innovation and the consistent delivery of high-quality, accessible products for prevention and treatment of ocular issues.
Key people at Bausch & Lomb.
Bausch & Lomb has 1 tracked investment across 1 company. The latest tracked deal is $93.0M Series B in Character Biosciences in March 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2025 | Character Biosciences | $93.0M Series B | Jamie Kasuboski | BoxOne Ventures, Industry Ventures, Innovation Endeavors, KDT Ventures, LifeForce Capital, Sanofi Ventures, Shane Neman, Joel Dudley, Catalio Capital, Jefferson Life Sciences, Section 32 |
Key people at Bausch & Lomb.